News: Breast Cancer Research Program

Tuya Pal, MD, Ingram Professor of Cancer Research and associate director for Cancer Health Disparities at Vanderbilt-Ingram Cancer Center, has been named to two cancer research leadership posts.

Continuous activation of cell surface receptors increases signaling that can promote oncogenic transformation. One receptor, EphA2, has been identified as a driver of lung cancer, but its interacting partners are not well characterized.

After serving as interim director since Jan. 1, Ben Ho Park, MD, PhD, Donna S. Hall Professor of Breast Cancer Research at Vanderbilt University Medical Center, has been named director of the Division of Hematology and Oncology.

Vanderbilt-Ingram Cancer Center’s Justin Balko, PharmD, PhD, has received a $100,000 research grant from the Mary Kay Foundation.

Two Vanderbilt-Ingram Cancer Center investigators have received financial support from Susan G. Komen for breast cancer research.

Testing for all metastatic breast cancer patients may be an optimal strategy for identifying additional patients with increased risk as well as response to targeted therapies.

Breast cancer researchers at Vanderbilt-Ingram Cancer Center have secured a fourth round of continuous Specialized Program of Research Excellence funding.

Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.

Vanderbilt-Ingram Cancer Center scientists have discovered a role for a tumor suppressor protein in skin wound healing.

Immunotherapies that take off the “brakes” on the adaptive anti-tumor response have worked well in melanoma and lung cancer but less so in breast cancers. That could change.